Spero Therapeutics, Inc.
SPRO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001701108
No open-market purchases or sales by Spero Therapeutics, Inc. insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $47.5M in total; no superinvestor holds it.
13F holders, Q1 2025
Institutional positions in Spero Therapeutics, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 38
- −11 vs. Q4 2024
- Shares held
- 15.1M
- −569.4K (−3.6%) vs. Q4 2024
- Total value
- $10.9M
- −$5.27M (−32.6%) vs. Q4 2024
- New holders
- 1
- 9 more added
- Sold out
- 12
- 10 more reduced
1 institution that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SPRO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 59 | $47.5M |
| Q1 2026 | 50 | $49.3M |
| Q4 2025 | 56 | $49.2M |
| Q3 2025 | 47 | $21.3M |
| Q2 2025 | 44 | $32.1M |
| Q1 2025 | 38 | $10.9M |
| Q4 2024 | 50 | $16.5M |
| Q3 2024 | 46 | $16.5M |
| Q2 2024 | 48 | $18.0M |
| Q1 2024 | 54 | $23.7M |
| Q4 2023 | 50 | $143.1M |
| Q3 2023 | 54 | $17.2M |
| Q2 2023 | 56 | $20.8M |
| Q1 2023 | 48 | $25.5M |
| Q4 2022 | 60 | $24.6M |
| Q3 2022 | 69 | $39.7M |
| Q2 2022 | 79 | $15.5M |
| Q1 2022 | 100 | $179.6M |
| Q4 2021 | 84 | $318.3M |
| Q3 2021 | 87 | $338.2M |
| Q2 2021 | 88 | $244.1M |
| Q1 2021 | 94 | $273.1M |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Spero Therapeutics, Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Anson Funds Management LP | 3,798,932 | $2.74M | 0.65% | −40,954−1.1% | Reduced |
| Pfizer Inc | 2,362,348 | $1.70M | 0.34% | 00.0% | Unchanged |
| Vanguard Group Inc | 1,763,620 | $1.27M | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 970,907 | $699.1K | 0.00% | −134,684−12.2% | Reduced |
| Alphabet Inc. | 889,979 | $640.8K | 0.04% | 00.0% | Unchanged |
| Murchinson Ltd. | 873,910 | $629.2K | 0.09% | 00.0% | Unchanged |
| Acadian Asset Management LLC | 871,212 | $626.0K | 0.00% | −168,710−16.2% | Reduced |
| ADAR1 Capital Management, LLC | 801,277 | $576.9K | 0.11% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 524,869 | $378.0K | 0.00% | +43,741+9.1% | Added |
| BlackRock, Inc. | 482,082 | $347.1K | 0.00% | −3,270−0.7% | Reduced |
| Monimus Capital Management, LP | 310,908 | $223.9K | 0.19% | 00.0% | Unchanged |
| Atlas Venture Life Science Advisors, LLC | 305,255 | $219.8K | 0.04% | 00.0% | Unchanged |
| Mackenzie Financial Corp | 209,031 | $150.5K | 0.00% | +21,472+11.4% | Added |
| Bridgeway Capital Management, LLC | 154,800 | $111.5K | 0.00% | −30,000−16.2% | Reduced |
| State Street Corp | 148,911 | $107.2K | 0.00% | 00.0% | Unchanged |
| DAFNA Capital Management LLC | 125,000 | $90.0K | 0.03% | 00.0% | Unchanged |
| Northern Trust Corp | 100,924 | $72.7K | 0.00% | +14,477+16.7% | Added |
| Squarepoint Ops LLC | 92,939 | $66.9K | 0.00% | +37,888+68.8% | Added |
| Citadel Advisors LLC | 61,316 | $44.1K | 0.00% | −111,556−64.5% | Reduced |
| JPMorgan Chase & Co | 60,817 | $43.8K | 0.00% | −807−1.3% | Reduced |
| Prudential Financial Inc | 56,000 | $40.3K | 0.00% | +6,800+13.8% | Added |
| Three Seasons Wealth, LLC | 30,000 | $21.6K | 0.01% | 00.0% | Unchanged |
| DLK Investment Management, LLC | 29,825 | $21.5K | 0.01% | +870+3.0% | Added |
| Charles Schwab Investment Management Inc | 28,565 | $20.6K | 0.00% | 00.0% | Unchanged |
| EP Wealth Advisors, LLC | 16,500 | $11.9K | 0.00% | +16,500 | New |
| Texas Yale Capital Corp. | 10,000 | $7.20K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 6,971 | $5.02K | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 5,565 | $4.01K | 0.00% | +18+0.3% | Added |
| FMR LLC | 5,056 | $3.64K | 0.00% | +767+17.9% | Added |
| Simplex Trading, LLC | 5,098 | $3.00K | 0.00% | −12−0.2% | Reduced |
| UBS Group AG | 2,826 | $2.04K | 0.00% | +2,685+1,904.3% | Added |
| Cullen/Frost Bankers, Inc. | 2,000 | $1.44K | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 200 | $144 | 0.00% | 00.0% | Unchanged |
| US Bancorp | 151 | $109 | 0.00% | −5,000−97.1% | Reduced |
| GWM Advisors LLC | 100 | $72 | 0.00% | 00.0% | Unchanged |
| SBI Securities Co., Ltd. | 60 | $43 | 0.00% | −153−71.8% | Reduced |
| CoreCap Advisors, LLC | 50 | $36 | 0.00% | 00.0% | Unchanged |
| BNP Paribas Arbitrage, SA | 12 | $9 | 0.00% | 00.0% | Unchanged |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −52,869−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −46,046−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −30,138−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −29,755−100.0% | Sold out |
| PFG Investments, LLC | 0 | $0 | 0.00% | −24,534−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −14,692−100.0% | Sold out |
| Dimensional Fund Advisors LP | 0 | $0 | 0.00% | −10,003−100.0% | Sold out |
| National Bank of Canada | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −929−100.0% | Sold out |
| Advisor Group Holdings, Inc. | 0 | $0 | 0.00% | −295−100.0% | Sold out |
| Richards, Merrill & Peterson, Inc. | 0 | $0 | 0.00% | −150−100.0% | Sold out |
| Federation des caisses Desjardins du Quebec | 0 | $0 | 0.00% | −30−100.0% | Sold out |
| WR Wealth Planners, LLC | – | – | – | – | Not filed |